The main rationale for the use of statins in hyperlipoproteinemia(a) is their ability to reduce the LDL-dependent portion of the risk for CVD in patients that have an overall higher CVD risk due to increased Lp(a) levels [26]. This evidence concerns the gene LPA and hyperlipoproteinemia.